COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,523 Articles (22,380 medRxiv, 8,143 bioRxiv)

Most recent first Previous |  Page 294: Articles 2931-2940  | Next

PRIEST - Predicting viral mutations with immune escape capability of SARS-CoV-2 using temporal evolutionary information
Saha, G., Sawmya, S., Saha, A., Tasnim, S., Akil, M. A., Rahman, M. S., Rahman, M. S.
10.1101/2023.08.11.552988 — Posted: 2023-08-14
Structural elucidation and antiviral activity of cathepsin L inhibitors with carbonyl and epoxide warheads
Falke, S., Lieske, J., Herrmann, A., Loboda, J., Gunther, S., Reinke, P. Y. A., Ewert, W., Karnicar, K., Usenik, A., Lindic, N., Sekirnik, A., Tsuge, H., Turk, V., Chapman, H. N., Hinrichs, W., Ebert, G., Turk, D., Meents, A.
10.1101/2023.08.11.552671 — Posted: 2023-08-14
Subphenotypes of Self-Reported Symptoms and Outcomes in Long COVID: a prospective cohort study with latent class analysis.
Kitsios, G. D., Blacka, S., Jacobs, J., Mirza, T., Naqvi, A., Gentry, H., Kessinger, C., Wang, X., Golubykh, K., Qurashi, H. M. S., Dodia, A., Risbano, M., Benigno, M., Emir, B., Weinstein, E., Bramson, C., Jiang, L., Dai, F., Szigethy, E., Mellors, J., Methe, B., Sciurba, F., Mehdi Nouraie, S., Morris, A.
10.1101/2023.08.09.23293901 — Posted: 2023-08-13
Analysis of SARS-CoV-2 Variant-Specific Serum Antibodies Post-Vaccination Utilizing Immortalized Human Hepatocyte-like Cells (HLC) to Assess Development of Protective Immunity
Collins, D. P., Steer, C. J.
10.1101/2023.08.08.23293863 — Posted: 2023-08-13
A community based cross-sectional study on impact assessment of COVID-19 on mental health in Central India
Gahwai, D. K., Dayama, S., Chhabra, R. K., Chandrakar, S. K., Mishra, A., Sahu, B., Sharma, M.
10.1101/2023.08.08.23293808 — Posted: 2023-08-13
Post-COVID conditions during Delta and early-Omicron SARS-CoV-2 variant periods among adults in the United States
Edwards, D. L., Logan, P., Feldstein, L., Accorsi, E., Fairlie, T., Saydah, S.
10.1101/2023.08.09.23293776 — Posted: 2023-08-13
Identifying facilitators and barriers to culturally responsive communication for racial, ethnic, sexual, and gender minoritized patients when screened for COVID-19 vaccinations: A Scoping Review Protocol
Kalita, N., Corr, P. G., Ward, M. C., Xavier, J., McDonald, P.
10.1101/2023.08.11.23293975 — Posted: 2023-08-12
Comparative Immunogenicity, Safety and Efficacy Profiles of four COVID-19 Vaccine types in healthy adults: Systematic Review cum Meta-analysis of Clinical Trial data
Yoong, S. Q., Bhowmik, P., Dutta, D.
10.1101/2023.08.10.23293964 — Posted: 2023-08-12
Pretrainable Geometric Graph Neural Network for Antibody Affinity Maturation
Cai, H., Zhang, Z., Wang, M., Zhong, B., Wu, Y., Ying, T., Tang, J.
10.1101/2023.08.10.552845 — Posted: 2023-08-11
Additive Manufacturing Leveraged Microfluidic Setup for Sample to Answer Colorimetric Detection of Pathogens
Yedire, S. G., Hosseini, I. I., Shieh, H., Jahromi, A. K., Fatah, T. A., Jalali, M., Mahshid, S.
10.1101/2023.08.10.552726 — Posted: 2023-08-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).